What the FDA labels say about taking them together
Elbasvir/grazoprevir and tacrolimus
Elbasvir/grazoprevir's FDA label of March 13, 2026 names tacrolimus in its drug interactions section; the tacrolimus labels PlainMeds reads (4) do not name elbasvir/grazoprevir. The elbasvir/grazoprevir label: “Frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events upon the initiation of co-administration is recommended.”
Check it at the source: the elbasvir/grazoprevir FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).
What does the elbasvir/grazoprevir label say about tacrolimus?
Elbasvir/grazoprevir label, drug interactionsConcomitant Drug Class/Drug Name: Immunosuppressants: Tacrolimus; Effect on Concentration ↓ = decrease, ↑ = increase: ↑ tacrolimus; Clinical Comment: Frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events upon the initiation of co-administration is recommended.
Source: FDA drug label (ZEPATIER), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 164dc02a-9180-426a-b8b5-04ab39d2bbd4), via openFDA; the full label on DailyMed
What does the tacrolimus label say about elbasvir/grazoprevir?
Tacrolimus's label (effective July 17, 2026) and its 3 other brand-application labels do not name elbasvir/grazoprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elbasvir/grazoprevir | Tacrolimus | |
|---|---|---|
| Labeled for | Hepatitis C | Organ transplant rejection, Eczema (atopic dermatitis) |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.970 per gram 0.1% ointment |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once